GlobeNewswire: Sera Prognostics, Inc. Contains the last 10 of 42 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:20:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/12/1665855/0/en/Sera-Prognostics-Receives-New-York-State-Approval-for-PreTRM-Testing.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Receives New York State Approval for PreTRM® Testing2018-12-12T13:00:00Z<![CDATA[SALT LAKE CITY, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company, announced today that the New York State Department of Health has issued a clinical laboratory permit for Sera to perform PreTRM® testing for pregnant women in the state of New York. The lab approval was based on the results of an on-site inspection and rigorous evaluation process. With this approval, Sera can now commercialize the PreTRM® test in New York, a very important health care market.]]>https://www.globenewswire.com/news-release/2018/11/27/1657346/0/en/Sera-Prognostics-Completes-Enrollment-of-Large-Multicenter-Prospective-Clinical-Study-of-PreTRM-Test.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test2018-11-27T13:00:00Z<![CDATA[TREETOP Study will Explore Enhancements to Sera’s Validated PreTRM® Test]]>https://www.globenewswire.com/news-release/2018/06/21/1527949/0/en/Sera-Prognostics-Appoints-Dr-Garrett-K-Lam-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Appoints Dr. Garrett K. Lam as Chief Medical Officer2018-06-21T14:00:00Z<![CDATA[Maternal fetal medicine expert joins Sera to improve pregnancy health globally Maternal fetal medicine expert joins Sera to improve pregnancy health globally]]>https://www.globenewswire.com/news-release/2018/06/19/1526635/0/en/Sera-Prognostics-Collaborates-with-Christiana-Care-Health-System-to-Launch-New-Preterm-Birth-Study-with-PreTRM-Test.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Collaborates with Christiana Care Health System to Launch New Preterm Birth Study with PreTRM® Test2018-06-19T14:00:00Z<![CDATA[AVERT PRETERM TRIAL studies the impact of interventions based on early risk identification AVERT PRETERM TRIAL studies the impact of interventions based on early risk identification]]>https://www.globenewswire.com/news-release/2018/02/12/1338983/0/en/Key-Strategies-for-Implementing-Proteomics-Based-Tests-Across-Disease-States-Highlighted-in-Current-Opinion-in-Biotechnology.html?f=22&fvtc=4&fvtv=12029Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology 2018-02-12T13:00:00Z<![CDATA[Xpresys® Lung and PreTRM® Tests Featured as Demonstrating Pathway to Successful Development and Clinical Implementation Xpresys® Lung and PreTRM® Tests Featured as Demonstrating Pathway to Successful Development and Clinical Implementation]]>https://www.globenewswire.com/news-release/2017/11/06/1175154/0/en/Sera-Prognostics-to-Present-at-the-11th-Annual-Canaccord-Genuity-Medical-Technologies-and-Diagnostics-Forum.html?f=22&fvtc=4&fvtv=12029Sera Prognostics to Present at the 11th Annual Canaccord Genuity Medical Technologies and Diagnostics Forum2017-11-06T15:00:00Z<![CDATA[SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.]]>https://www.globenewswire.com/news-release/2017/09/05/1107808/0/en/Sera-Prognostics-to-Present-at-the-Baird-2017-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=12029Sera Prognostics to Present at the Baird 2017 Global Healthcare Conference2017-09-05T14:49:00Z<![CDATA[SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Baird Global Healthcare Conference in New York City. Dr. Critchfield’s presentation will take place at 9:05 AM E.T. on Thursday, September 7th, at the InterContinental New York Barclay Hotel.]]>https://www.globenewswire.com/news-release/2017/06/29/1031833/0/en/Sera-Prognostics-Receives-Accreditation-from-College-of-American-Pathologists.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Receives Accreditation from College of American Pathologists2017-06-29T13:00:00Z<![CDATA[SALT LAKE CITY, June 29, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sera Prognostics, Inc., based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.]]>https://www.globenewswire.com/news-release/2017/06/26/1029079/0/en/Sera-Prognostics-Announces-Analytical-Validation-Study-Published-in-Clinical-Mass-Spectrometry.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Announces Analytical Validation Study Published in Clinical Mass Spectrometry2017-06-26T14:00:00Z<![CDATA[SALT LAKE CITY, June 26, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that its recent analytical study, Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.]]>https://www.globenewswire.com/news-release/2017/05/17/987016/0/en/Sera-Prognostics-Appoints-Nadia-Altomare-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=12029Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer2017-05-17T14:00:00Z<![CDATA[SALT LAKE CITY, May 17, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, announced today that Nadia F. Altomare has joined the company as chief commercial officer.  Ms. Altomare will lead all commercial activities for Sera as the company makes its groundbreaking PreTRM® test available to physicians and patients.  The PreTRM test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.]]>